Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Translocation kidney cancer after chemotherapy in childhood

This article out of Johns Hopkins reviewed the risk of renal cell carcinoma occurring as a secondary malignancy after chemotherapy in childhood.

21 Apr 2007

Genelabs Tech reaches agreement with FDA on special protocol assessment for phase III trial of Prestara in lupus

Genelabs Technologies has announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial of Prestara (prasterone) for treatment of systemic lupus erythematosus (lupus).

4 Apr 2007

Estradiol and its metabolites and their association with knee osteoarthritis

Osteoarthritis, which usually develops between the ages of 40 and 50, is more prevalent in women. It is thought that sex hormones may play a role in developing the disease, since they can be involved in inflammation of the tissues affected by it.

26 Jul 2006

Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus

Trust between a patient and doctor is a key factor in promoting improved quality of life, compliance with treatment, and better health outcomes.

31 May 2006

Researchers find gene connected to Lupus

Researchers at the University of Minnesota have identified a variant of a gene that is present in most people with lupus, a complex and chronic autoimmune disease.

20 Apr 2006

Epstein-Barr virus infection linked to multiple sclerosis

Young adults with high levels of antibodies against the Epstein-Barr virus, the virus that most often causes mononucleosis, may be more likely to develop multiple sclerosis 15 to 20 years later, according to a study in the Archives of Neurology.

11 Apr 2006

Anti-malarials most effective in lupus patients genetically at risk of high levels of TNF-alpha

Anti-malarial drugs are most effective in people with lupus who are genetically predisposed to high levels of tumour necrosis factor alpha and low levels of the cytokine IL-10.

16 Feb 2006

Identity Swap: Finding the variants that human history has favoured

Sequence differences in less than 0.2% of the 3-billion-base human genome play a vital role in a bewildering variety of human disease. Researchers from the Wellcome Trust Sanger Institute and the Cambridge University’s Cambridge Institute for Medical Research, together with international colleagues report in PLoS Genetics their detailed maps of differences implicated in disease as well as genes that are unchanged in recent human history.

26 Jan 2006

Breakthrough in lupus research

A major breakthrough in lupus research - one that may fundamentally change thinking on how the disease affects behavior and cognition - was reported in the January 17, 2006 Proceedings of the National Academy of Sciences (PNAS).

25 Jan 2006

Study explains complex infection fighting mechanism

Yale School of Medicine researchers report in Nature Immunology how infection fighting mechanisms in the body can distinguish between a virus and the healthy body, shedding new light on auto immune disorders.

11 Jan 2006

Women suffering lupus OK to take oral contraceptives

Major study of women with either inactive or stable systemic lupus erythematosus (lupus) – a disease in which the body's immune system mistakenly attacks and damages healthy tissues of the skin, joints and internal organs – were able to take oral contraceptives without increased risk of flares, or periods of increased disease activity, that characterize the disease.

22 Dec 2005

Lupus discovery may improve treatment

Researchers at Wake Forest University School of Medicine and the University of Virginia hope to reset part of the "epigenetic code" in lupus patients and thus improve treatment.

7 Nov 2005

First study to test the role of RNA chemical modifications on immunity

The investigators published their findings in the August issue of Immunity. "We think this study will open a new area of research in understanding how our immune systems protect us," says Weissman.

23 Aug 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

Scientists shed new light on how protein Ro creates RNA quality control system for cells

A report by Yale scientists in the journal Cell sheds new light on how the protein Ro, a major autoantigen in patients with autoimmune disease, recognizes misfolded RNAs, creating a RNA quality control system for cells.

1 Jun 2005

La Jolla Pharmaceutical provides update on Riquent

La Jolla Pharmaceutical Company today announced that it has received "fast track" designation for Riquent (abetimus sodium) for the treatment of lupus renal disease from the U.S. Food and Drug Administration (FDA).

31 May 2005

New gene shows way for autoimmune disease

A new gene suspected to contribute to autoimmune diseases such as type 1 diabetes and lupus - a condition in which the body’s own immune system attacks organs such as the kidneys and skin - has been discovered by Australian National University (ANU) immunologists.

30 May 2005

Researchers show protein's role in stopping bacterial-induced inflammation

In findings that could have implications for autoimmune disorders and drug-resistant bacterial infections, researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key protein involved in the appropriate shut-down of inflammation following an immune response to invading pathogens.

28 Apr 2005

Epstein-Barr virus may increase risk of lupus

Almost everyone has been infected with Epstein-Barr virus (EBV), a member of the herpes family and one of the most common human viruses.

7 Apr 2005

Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein

Aggressive therapy with statins -- drugs that inhibit cholesterol synthesis -- works better than moderate statin therapy in reducing fats and proteins in the blood that have been linked to atherosclerosis, a new multi-center study concludes. Statins’ effects on both complex compounds appear beneficial in cutting patients’ cardiovascular risks.

6 Jan 2005